Clinical trial
A Long Term, Safety Study of Apricitabine in HIV-infected Subjects
NCT00367952 · Avexa, Industry · Completed
Key facts
| NCT number | NCT00367952 |
|---|---|
| Title | A Long Term, Safety Study of Apricitabine in HIV-infected Subjects |
| Official title | An Open Label Long Term Safety Extension Study of Apricitabine in Treatment-experienced HIV-1 Infected Subjects |
| Lead sponsor | Avexa, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infection |
| Intervention type | Drug |
| Interventions | apricitabine |
| Enrollment | 42 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2010 |
| Completion | Jan 1, 2010 |
| First posted | Aug 24, 2006 |
| Last update posted | Jun 23, 2011 |
| Countries | Australia |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: